Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Share This Post

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients

The Food and Drug Administration has approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a Novartis company) as a way to treat GEP-NETs in kids 12 years and older who are positive for the somatostatin receptor (SSTR). GEP-NETs can be in the foregut, midgut, or hindgut. Permission for the use of Lutetium Lu 177 dotatate in adults was granted in 2018.

This marks the initial approval by the FDA of a radioactive medicine, often known as a radiopharmaceutical, for children aged 12 and above who have SSTR-positive GEP-NETs.

Efficacy and Safety

The approval was granted after evaluating pharmacokinetic (PK), dosimetry, and safety data from the ongoing international study called NETTER-P (NCT04711135). This study focuses on lutetium Lu 177 dotatate and its effectiveness in treating adolescent patients with locally advanced/inoperable or metastatic SSTR-positive GEP-NETs or pheochromocytoma/paraganglioma (PPGL). The study is open-label and single-arm, conducted at multiple centers.

The approval was also granted based on the extrapolation of efficacy results observed in the NETTER-1 (NCT01578239) trial. This clinical trial was a randomized, multicenter, open-label, active-controlled study involving 229 patients with locally advanced/inoperable or metastatic SSTR-positive midgut carcinoid tumors. The findings from this trial provided additional support for the original approval of lutetium Lu 177 dotatate in adult patients.

The safety of the treatment was assessed in a total of 9 pediatric patients in the NETTER-P study, out of which 4 patients had GEP-NETs. The radiation doses that specific organs absorbed and the occurrence of any unfavorable effects after the initial treatment cycle were the main metrics of interest. As an extra outcome measure, the study looked at any bad reactions that happened right away after lutetium Lu 177 dotatate was given. The adverse reaction profile found in the NETTER-P study was comparable to that observed in the adult population.

The suggested dosage for lutetium Lu 177 dotatate is 7.4 GBq (200 mCi) per 8 weeks (± 1 week) for a total of 4 treatments. Administer premedications and concurrent drugs according to the prescribed guidelines. An obligation was issued after the marketing phase to evaluate the enduring safety of lutetium Lu 177 dotatate in teenagers.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T-Cell therapy

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation

CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy involves genetically modifying a patient’s T cells to target and destroy cancerous B cells. Clinical trials indicate significant response rates, with some patients achieving complete remission. Despite challenges like potential severe side effects, CAR T cell therapy represents a groundbreaking approach, offering hope for improved outcomes in this difficult-to-treat condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy